BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 20616215)

  • 1. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
    Horton HM; Bernett MJ; Peipp M; Pong E; Karki S; Chu SY; Richards JO; Chen H; Repp R; Desjarlais JR; Zhukovsky EA
    Blood; 2010 Oct; 116(16):3004-12. PubMed ID: 20616215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
    Funakoshi S; Longo DL; Murphy WJ
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
    Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
    Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
    Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
    Front Immunol; 2019; 10():562. PubMed ID: 30984171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
    Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
    Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
    White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
    J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.
    McEarchern JA; Oflazoglu E; Francisco L; McDonagh CF; Gordon KA; Stone I; Klussman K; Turcott E; van Rooijen N; Carter P; Grewal IS; Wahl AF; Law CL
    Blood; 2007 Feb; 109(3):1185-92. PubMed ID: 17038522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
    Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
    FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
    Heider KH; Kiefer K; Zenz T; Volden M; Stilgenbauer S; Ostermann E; Baum A; Lamche H; Küpcü Z; Jacobi A; Müller S; Hirt U; Adolf GR; Borges E
    Blood; 2011 Oct; 118(15):4159-68. PubMed ID: 21795744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
    Qi J; Chen SS; Chiorazzi N; Rader C
    Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
    Zalevsky J; Leung IW; Karki S; Chu SY; Zhukovsky EA; Desjarlais JR; Carmichael DF; Lawrence CE
    Blood; 2009 Apr; 113(16):3735-43. PubMed ID: 19109559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
    Richman LP; Vonderheide RH
    Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.